dapagliflozin Archives - International Society of Nephrology

ISN Journal editorial selections on dapagliflozin, Thailand’s CKD strategy, and misleading pseudocrescents in glomerulopathy

Kidney International®  New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes Dapagliflozin improves kidney outcomes in chronic kidney disease (CKD), but the mechanisms behind these benefits are not fully understood. This DAPA-CKD proteomic analysis found that dapagliflozin modifies biological pathways linked to CKD progression, particularly those involving inflammation, fibrosis, and tissue remodeling. The...

Explore the latest ISN Global Trials Focus selections featuring a “Trial of the month” on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan

ISN-ACT Global Trials Focus editorial team member Michele Provenzano summarizes the design and outcomes of the latest "Trial of the month" featured in ISN-ACT Global Trials Focus. Trial of the month: DAPA-tolvaptan: First trial of SGLT2 inhibition in ADPKD with background tolvaptan therapy Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan Uchiyama...

Tag - dapagliflozin